The effect of prostaglandins, branched-chain amino acids and other drugs on the outcome of experimental acute porcine hepatic failure.
Prostaglandins, N-acetyl-cysteine, cholestyramine and essential phospholipids have all been shown to protect experimental animals from severe hepatic damage in various models when used prophylactically. Silibinin has been used in the treatment of Amanita phalloides poisoning. Branched-chain amino acids have been recommended in acute hepatic failure. We have used all these forms of therapy at the time of initiation of hepatic failure in a reliable pig model. Of the above, only prostaglandins have been shown to reverse the effects of the hepatic insult in terms of prolonged survival and histological changes. Although conventional liver function tests and plasma amino acids in prostaglandin-treated animals are not improved, cerebrospinal fluid amino acids remain normal, in contrast to the other groups of untreated and treated hepatic failure animals.
D000111:Acetylcysteine / Q000627:therapeutic use; D000597:Amino Acids, Branched-Chain / Q000627:therapeutic use*; D000601:Amino Acids, Essential / Q000097:blood / Q000134:cerebrospinal fluid; D000818:Animals; D002251:Carbon Tetrachloride; D002792:Cholestyramine Resin / Q000627:therapeutic use; D004195:Disease Models, Animal; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D010713:Phosphatidylcholines / Q000627:therapeutic use; D011453:Prostaglandins / Q000627:therapeutic use*; D012838:Silymarin / Q000627:therapeutic use; D013552:Swine
D000597:Amino Acids, Branched-Chain; D000601:Amino Acids, Essential; D010713:Phosphatidylcholines; D011453:Prostaglandins; D012838:Silymarin; D002792:Cholestyramine Resin; D002251:Carbon Tetrachloride; D000111:Acetylcysteine